NGENF News and Press, NervGen Pharma Corp From 08/21/20

NervGen Pharma ( OTCQX:NGENF ) : Q2 GAAP EPS of -$0.09. The net cash burn for Q2 2020 from operating activities was ~$1.4M. Cash balance of $3.5M Press Release More news on: NervGen Pharma Corp., Earnings news and commentary, Healthcare stocks news, ,

Vancouver, British Columbia--(Newsfile Corp. - August 21, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its f...

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...

Vancouver, British Columbia--(Newsfile Corp. - July 27, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (" NervGen " the " Company "), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that th...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 22, 2020 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“ NervGen ” the “ Company ”), a biotech company dedicate...

Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) -   NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced ...

Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) -   NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced t...

NervGen Pharma ( OTCQX:NGENF ): Q1 GAAP EPS of -C$0.06. More news on: NervGen Pharma Corp., Earnings news and commentary, Healthcare stocks news, , Read more ...

Vancouver, British Columbia--(Newsfile Corp. - June 1, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its fi...

Vancouver, British Columbia--(Newsfile Corp. - May 20, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce ...